According to a bullish Wall Street analyst, Abbott Laboratories (NYSE: ABT) stock could outperform for investors. Following the company's latest earnings report, Matt Miksic from Barclays maintained his buy rating and raised his price target to $143 per share.At recent prices, Miksic's price target predicts a gain of about 32% once the rest of the stock market sees Abbott Laboratories in the same light as he does.In the "pro" column, Abbott Laboratories recently announced an advantageous deal with Medtronic (NYSE: MDT), another leading medical device maker.